Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards Lifesciences's other long-term assets for the quarter that ended in Jun. 2026 was CHF1,221 Mil.
Edwards Lifesciences's quarterly other long-term assets
declined
from Dec. 2025 (CHF1,489 Mil) to Mar. 2026 (CHF1,446 Mil) but then
stayed the same
from Mar. 2026 (CHF1,446 Mil) to Jun. 2026 (CHF1,221 Mil).
Edwards Lifesciences's annual other long-term assets
increased
from Dec. 2023 (CHF1,318 Mil) to Dec. 2024 (CHF1,538 Mil) but then
declined
from Dec. 2024 (CHF1,538 Mil) to Dec. 2025 (CHF1,489 Mil).
Edwards Lifesciences Other Long Term Assets Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's Other Long Term Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.
What does a Other Long Term Assets of CHF1,221 Mil mean?
Edwards Lifesciences (XSWX:EW) has a Other Long Term Assets of CHF1,221 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Other Long Term Assets too high?
Edwards Lifesciences' current Other Long Term Assets is CHF1,221 Mil. Overall, Edwards Lifesciences has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Other Long Term Assets compare to BSX and DXCM?
Edwards Lifesciences' Other Long Term Assets of CHF1,221 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Devices & Instruments company?
A good Other Long Term Assets depends on the Medical Devices & Instruments industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Other Long Term Assets is CHF1,221 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Other Long Term Assets of CHF1,221 Mil. The stock's GF Value™ is CHF75.68, compared to a current price of CHF74.11 — trading 2.1% below its estimated fair value. The current Other Long Term Assets is CHF1,221 Mil. Edwards Lifesciences' overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Other Long Term Assets is CHF1,221 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of CHF74.11 is trading 2.1% below its estimated GF Value™ of CHF75.68.
Key valuation signals for XSWX:EW:
Other Long Term Assets: CHF1,221 Mil
GF Value™: CHF75.68 vs. price of CHF74.11 (2.1% below fair value)
No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
98GF Score
Get the complete analysis for XSWX:EW
Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EW has been successfully added to your 
